噻托溴铵治疗稳定期慢性阻塞性肺疾病疗效观察被引量：15

The curative effect of tiotropium bromide in treating stable chronic obstructive pulmonary disease

在线阅读下载PDF

导出

摘要目的评价噻托溴铵治疗稳定期慢性阻塞性肺疾病(COPD)的疗效和安全性。方法将50例年龄40～75岁稳定期Ⅰ、Ⅱ级COPD患者随机分为治疗组和对照组。治疗组吸入噻托溴铵干粉剂(18μg,每日1次)治疗13周。在治疗前,治疗4周及12周分别测定肺功能。结果治疗组第一秒用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1/FVC、FEV1占预计值的百分比上升值较对照组有有显著性差异(P<0.05)。噻托溴铵的常见不良反应为口干(2例,8%),无心血管系统异常和心电图异常报告。结论噻托溴铵对于稳定期Ⅰ、Ⅱ级COPD患者疗效显著且安全可靠。 Objective To evaluate the effect and safety of tiotropium bromide in treating stable ehronie obstruetive puhnonary disease（COPD）. Methods A randomized clinieal trial was eondueted in 50 patients （age 40 -75 years） with mild and moderate COPD. 25 patients in tiotropium group were treated by tiotropium bromide powder（ 18μg,qd, inhaled） and another 25 patients in controlled group were given no medizine altogether for 13 weeks. The spirometry was eondueted at before treatment, 2 weeks and 4 weeks after treatment. Results Foreed expiratory volum in one seeond（ FEV1 ） ,foreed vital eapaeity（FVC） , FEV1/FVC, FEV1/Pred% were signifieantly inereased after treatment in the tiotropium groups （P 〈0. 05 ）. The major adverse event in the tiotropium group was dry mouth （8%）. No eardiae disorder or abnormal eleetroeardiogram was reported. Conclusion Tiotropium bromide is an effeetive and safe bronehodilator in the treating mild to moderate stable COPD patients.

作者夏秋萍陈建荣陶一江

机构地区南通大学第二附属医院(江苏省南通市第一人民医院呼吸科)

出处《临床肺科杂志》 2007年第12期1327-1328,共2页 Journal of Clinical Pulmonary Medicine

关键词噻托溴铵阻塞性肺疾病肺功能 Tiotropium bromide ehronie obstruetive pulmonary disease spirometry

分类号 R563.9 [医药卫生—呼吸系统]

引文网络
相关文献

参考文献7

1郑劲平,康健,蔡柏蔷,周新,曹兆龙,白春学,钟南山.吸入噻托溴铵干粉与异丙托溴铵定量气雾剂治疗慢性阻塞性肺疾病的疗效与安全性比较[J].中华结核和呼吸杂志,2006,29(6):363-367. 被引量：159
2Decrarner M,Celli B,Tashkin DP,et al.Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD:the UPLIFT trial.COPD,2004,1 (2):303-312.
3Pieper MP,Chaudhary NI,Park JE.Acetylcholine-induced proliferation of fibroblasts and myofibroblasts in vitro is inhibited by tiotropium bromide.Life Sci.2007,80 (24-25):2270-2273.
4Santus P,Centanni S,Morelli N,et al.Tiotropium is leas likely to induce oxygen desaturation in stable COPD patients compared to long-acting beta(2) -agonists.Respir Med,2007,101 (8):1798-1803.
5Barr RG,Bourbeau J,Camargo CA,et al.Tiotropium for stable chronic obstructive pulmonary disease:A meta-analysis.Thorax,2006,61(10):854 -862.
6Van Noord JA,Aumann JL,Janssens E,et al.Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD.Chest,2006,129(3):509 -517.
7Breekveldt-Postma NS,Koerselman J,Erkens JA,et al.Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.Respir Med,2007,101 (7):1398-1405

二级参考文献11

1刘升明,王小平,王大礼,周玉民,吕嘉春,郑劲平,钟南山,冉丕鑫.广东部分地区慢性阻塞性肺疾病发病状况调查[J].中华医学杂志,2005,85(11):747-752. 被引量：151
2Barnes PJ,Stockley RA.COPD:current therapeutic interventions and future approaches.Eur Respir J,2005,25:1084-1106.
3Disse B,Reichl R,Speck G,et al.Ba 679 BR,a novel long-acting anticholinergic bronchodilator.Life Sci,1993,52:537-544.
4Takahashi T,Belvisi MG,Patel H,et al.Effect of Ba 679 BR,a novel long-acting anticholinergic agent,on cholinergic neurotransmission in guinea pig and human airways.Am J Respir Crit Care Med,1994,150(6 Pt 1):1640-1645.
52003 Update:Workshop Report,Global Strategy for Diagnosis,Management,and Prevention of COPD.National Heart,Lung,and Blood Institute and World Health Organization,Global initiative for chronic obstructive lung disease (GOLD).Available from:http://www.goldeopd.org/
6Casaburi R,Mahler DA,Jones PW,et al.A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.Eur Respir J,2002,19:217-224.
7Littner MR,Ilowite JS,Tashkin DP,et al.Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease.Am J Respir Crit Care Med,2000,161 (4 Pt 1):1136-1142.
8Casaburi R,Briggs DD Jr,Donohue JF,et al.The spirometric efficacy of once-daily dosing with tiotropium in stable COPD:a 13-week multicenter trial.The US Tiotropium Study Group.Chest,2000,118:1294-1302.
9O'Donnell DE,Fluge T,Gerken F,et al.Effects of tiotropium on lung hyperinflation,dyspnoea and exercise tolerance in COPD.Eur Respir J,2004,23:832-840.
10Maltais F,Hamilton A,Marciniuk D,et al.Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.Chest,2005,128:1168-1178.